Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.850
+0.020 (0.52%)
Nov 3, 2026, 1:10 PM EST - Market open
Recursion Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Recursion Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $7.32. The average 1-year stock price forecast is 90.05% higher than the current stock price, while the lowest is $4.00 (+3.90%) and the highest is $10 (+159.74%).
Price Target: $7.32 (+90.05%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Recursion Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 5 | 5 | 4 | 4 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Buy Reiterates $8 | Buy | Reiterates | $8 | +107.79% | Oct 19, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Reiterates $5.3 → $5.9 | Hold | Reiterates | $5.3 → $5.9 | +53.25% | Oct 16, 2026 |
| Bank of America Securities | Bank of America Securities | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +55.84% | Oct 16, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Sep 15, 2026 |
| TD Cowen | TD Cowen | Hold Maintains n/a | Hold | Maintains | n/a | n/a | Aug 6, 2026 |
Financial Forecast
Revenue This Year
41.78M
from 74.68M
Decreased by -44.05%
Revenue Next Year
53.03M
from 41.78M
Increased by 26.91%
EPS This Year
-0.93
from -1.44
EPS Next Year
-0.87
from -0.93
EPS and Forward PE are based on non-GAAP adjusted numbers.